Dr. Reddy’s Announces the Launch of Eszopiclone Tablets C-IV

Dr. Reddy’s Announces the Launch of Eszopiclone Tablets C-IV

 India, Apr 16, 2014 (BUSINESS WIRE) -- Dr. Reddy’s Laboratories RDY 0.00%  announced today that it has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA® (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration (USFDA).

The LUNESTA® (eszopiclone) tablets C-IV brand and generic combined had U.S. sales of approximately $887 Million MAT for the most recent twelve months ending in January 2014 according to IMS Health*.

Dr. Reddy’s Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.